Medulloblastoma comprises four distinct molecular variants.
暂无分享,去创建一个
Hendrik Witt | Andrey Korshunov | Thomas Hielscher | Eric Bouffet | Steven C Clifford | P. Northcott | S. Pfister | J. Rutka | C. Hawkins | T. Hielscher | H. Witt | A. Korshunov | P. French | Michael D. Taylor | C. Eberhart | S. Mack | S. Clifford | E. Bouffet | Paul A Northcott | Cynthia E Hawkins | James T Rutka | Michael D Taylor | Charles G Eberhart | Stefan Pfister | Stephen Mack | Pim French
[1] Roger E. Taylor,et al. Nodule Formation and Desmoplasia in Medulloblastomas—Defining the Nodular/Desmoplastic Variant and Its Biological Behavior , 2007, Brain pathology.
[2] E. Lander,et al. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.
[3] F. Berthold,et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. , 2009, Neuro-oncology.
[4] Kristin L. Sainani,et al. Gender affects survival for medulloblastoma only in older children and adults: A study from the surveillance epidemiology and end results registry , 2009, Pediatric blood & cancer.
[5] R. McLendon,et al. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. , 2005, Cancer research.
[6] U. Tabori,et al. Distinctive clinical course and pattern of relapse in adolescents with medulloblastoma. , 2006, International Journal of Radiation Oncology, Biology, Physics.
[7] Axel Benner,et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Jill P. Mesirov,et al. Subclass Mapping: Identifying Common Subtypes in Independent Disease Data Sets , 2007, PloS one.
[9] J. Trojanowski,et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] K. Shah,et al. Increased p53 immunopositivity in anaplastic medulloblastoma and supratentorial PNET is not caused by JC virus , 2005, BMC Cancer.
[11] G. Rao. The miR-17/92 Polycistron Is Up-regulated in Sonic Hedgehog–Driven Medulloblastomas and Induced by N-myc in Sonic Hedgehog–Treated Cerebellar Neural Precursors , 2010 .
[12] F. Kokocinski,et al. Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. , 2004, Cancer research.
[13] M. Daly,et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.
[14] Pablo Tamayo,et al. Metagenes and molecular pattern discovery using matrix factorization , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[15] R H Perry,et al. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. , 1997, Cancer research.
[16] M. Chintagumpala,et al. FOXG1 dysregulation is a frequent event in medulloblastoma , 2007, Journal of Neuro-Oncology.
[17] J. Biegel,et al. Isochromosome 17q Is a Negative Prognostic Factor in Poor-Risk Childhood Medulloblastoma Patients , 2005, Clinical Cancer Research.
[18] J. Rutka,et al. A Clinicobiological Model Predicting Survival in Medulloblastoma , 2004, Clinical Cancer Research.
[19] J. Biegel,et al. Immunohistochemical Analysis of hSNF5/INI1 in Pediatric CNS Neoplasms , 2004, The American journal of surgical pathology.
[20] R. Tibshirani,et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[21] Claire L Weston,et al. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[23] T. Merchant,et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. , 2006, The Lancet. Oncology.
[24] Emmanuel Barillot,et al. Beta‐catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics , 2009, The Journal of pathology.
[25] G. Riggins,et al. Genomic amplification of orthodenticle homologue 2 in medulloblastomas. , 2005, Cancer research.
[26] J. Crolla,et al. Clinical and molecular stratification of disease risk in medulloblastoma , 2001, British Journal of Cancer.
[27] L. Rorke,et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] J. Biegel,et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. , 1999, Cancer research.
[29] D. Ellison,et al. Wnt/Wingless Pathway Activation and Chromosome 6 Loss Characterise a Distinct Molecular Sub-Group of Medulloblastomas Associated with a Favourable Prognosis , 2006, Cell cycle.
[30] T. Curran,et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Paul A. Northcott,et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma , 2009, Nature Genetics.
[32] Amar Gajjar,et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Dirk Troost,et al. Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features , 2008, PloS one.
[34] T. Poggio,et al. Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.